📊 ENDV Key Takeaways
Is ENDV a Good Investment? Thesis Analysis
Endonovo Therapeutics is in severe financial distress with negative stockholders' equity of -$23.0M, indicating the company is technically insolvent. Despite reporting a $8.5M net income anomaly, the company is burning cash at -$407K in free cash flow, has zero liquidity, and minimal revenue of $134.3K cannot support $7.1M in long-term debt and $23.8M in total liabilities.
Why Buy ENDV? Key Strengths
- Exceptional gross margin of 96.4% indicates strong pricing power on products sold
- Revenue growth of 110.2% YoY shows market demand for offerings
- Minimal capital expenditure needs suggest asset-light business model
ENDV Investment Risks to Consider
- Negative stockholders' equity of -$23.0M represents technical insolvency and existential solvency risk
- Zero cash and equivalents with negative operating cash flow of -$404.4K indicates immediate liquidity crisis
- Revenue of $134.3K cannot service $7.1M long-term debt and $23.8M total liabilities; unsustainable capital structure
- Current ratio and quick ratio of 0.00x confirm complete inability to meet short-term obligations
- Anomalous $8.5M net income amid operational losses suggests one-time gains or accounting adjustments masking underlying distress
Key Metrics to Watch
- Operating cash flow trend - must turn positive to indicate business viability
- Cash position and liquidity - any additional capital raise or debt restructuring
- Revenue growth sustainability - whether 110% growth can accelerate to meaningful absolute levels ($1M+)
- Stockholders' equity path to positive - requires sustained profitability or capital injection
ENDV Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ENDV Profitability Ratios
ENDV vs Healthcare Sector
How ENDONOVO THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENDV Overvalued or Undervalued?
Based on fundamental analysis, ENDONOVO THERAPEUTICS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENDV Balance Sheet & Liquidity
ENDV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ENDONOVO THERAPEUTICS, INC.'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
ENDV Growth Metrics (YoY)
ENDV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $1.5K | -$603.4K | $0.00 |
| Q2 2023 | $650 | $2.1M | $0.00 |
| Q1 2023 | $2.3K | -$2.4M | $0.00 |
| Q3 2022 | $7.8K | -$603.4K | $0.00 |
| Q2 2022 | $650 | -$1.3M | $-0.02 |
| Q1 2022 | $2.3K | -$2.4M | $-0.03 |
| Q3 2021 | $7.8K | -$1.1M | $-0.02 |
| Q2 2021 | $30.3K | -$1.3M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENDV Capital Allocation
ENDV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ENDONOVO THERAPEUTICS, INC. (CIK: 0001528172)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENDV
What is the AI rating for ENDV?
ENDONOVO THERAPEUTICS, INC. (ENDV) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENDV's key strengths?
Claude: Exceptional gross margin of 96.4% indicates strong pricing power on products sold. Revenue growth of 110.2% YoY shows market demand for offerings.
What are the risks of investing in ENDV?
Claude: Negative stockholders' equity of -$23.0M represents technical insolvency and existential solvency risk. Zero cash and equivalents with negative operating cash flow of -$404.4K indicates immediate liquidity crisis.
What is ENDV's revenue and growth?
ENDONOVO THERAPEUTICS, INC. reported revenue of $134.3K.
Does ENDV pay dividends?
ENDONOVO THERAPEUTICS, INC. does not currently pay dividends.
Where can I find ENDV SEC filings?
Official SEC filings for ENDONOVO THERAPEUTICS, INC. (CIK: 0001528172) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENDV's EPS?
ENDONOVO THERAPEUTICS, INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENDV a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, ENDONOVO THERAPEUTICS, INC. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENDV stock overvalued or undervalued?
Valuation metrics for ENDV: ROE of N/A (sector avg: 15%), net margin of 6,351.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENDV stock in 2026?
Our dual AI analysis gives ENDONOVO THERAPEUTICS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ENDV's free cash flow?
ENDONOVO THERAPEUTICS, INC.'s operating cash flow is $-404.4K, with capital expenditures of $2.6K. FCF margin is -303.1%.
How does ENDV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6,351.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).